Viking Therapeutics' oral obesity drug has shown promising results, with an average weight loss of about 8% after four weeks at the highest dose, raising expectations among analysts. Despite a 9% drop in shares following the announcement, experts noted the data's potential, comparing it favorably to competitors like Wegovy and Zepbound. Viking plans to initiate a Phase 2 study later this year while advancing its injectable version to Phase 3 trials.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
